Nuvalent, Inc. — Investor Relations & Filings
Filings indexed
506
across all filing types
Latest filing
2026-05-07
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
NUVL
Nuvalent, Inc. is a clinical-stage company developing precisely targeted therapies for patients with cancer. Leveraging deep expertise in chemistry and structure-based drug discovery, the company designs innovative small molecule kinase inhibitors. These therapies are engineered to overcome the limitations of existing treatments by addressing the dual challenges of drug resistance and kinase selectivity. Nuvalent is advancing a pipeline of novel drug candidates with parallel lead programs targeting ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). The company's portfolio includes NVL-655, an ALK-selective inhibitor that has received U.S. FDA Breakthrough Therapy Designation.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Nuvalent, Inc. (0001861560) (Filer) | 2026-05-07 | English | |
| 8-K - Nuvalent, Inc. (0001861560) (Filer) | 2026-05-07 | English | |
| ARS - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-28 | English | |
| DEF 14A - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-28 | English | |
| 8-K - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-07 | English | |
| 4 - Nuvalent, Inc. (0001861560) (Issuer) | 2026-03-30 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42789675 | 10-Q - Nuvalent, Inc. (0001861560) (Filer) | 2026-05-07 | English | ||
| 42789245 | 8-K - Nuvalent, Inc. (0001861560) (Filer) | 2026-05-07 | English | ||
| 38165707 | ARS - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-28 | English | ||
| 38165685 | DEF 14A - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-28 | English | ||
| 33699756 | 8-K - Nuvalent, Inc. (0001861560) (Filer) | 2026-04-07 | English | ||
| 33092910 | 4 - Nuvalent, Inc. (0001861560) (Issuer) | 2026-03-30 | English | ||
| 33035778 | 144 - Nuvalent, Inc. (0001861560) (Subject) | 2026-03-24 | English | ||
| 32900006 | 4 - NUVALENT, INC. (0001861560) (Filer) | 2026-03-02 | English | ||
| 32900007 | 4 - NUVALENT, INC. (0001861560) (Filer) | 2026-03-02 | English | ||
| 32900009 | 10-K - NUVALENT, INC. (0001861560) (Filer) | 2026-02-26 | English | ||
| 32900008 | 8-K - NUVALENT, INC. (0001861560) (Filer) | 2026-02-26 | English | ||
| 32108228 | SCHEDULE 13G/A Filing | 2026-02-12 | English | ||
| 32108227 | 4 Filing | 2026-02-02 | English | ||
| 13454945 | 4 | 2026-01-23 | English | ||
| 13454948 | Regulatory Filings 2026 | 2026-01-22 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Adlai Nortye Ltd.
A clinical-stage biopharma firm developing cancer immunothe…
|
ANL | KY | Manufacturing |
|
ADLINE CHEM LAB LIMITED
Produces APIs, chemical intermediates, and specialty chemic…
|
524604 | IN | Manufacturing |
|
ADMA BIOLOGICS, INC.
Biopharmaceutical company that develops and manufactures pl…
|
ADMA | US | Manufacturing |
|
Advectus Life Sciences Inc.
Advances drug delivery systems using proprietary nanopartic…
|
AVXSF | CA | Manufacturing |
|
Adverum Biotechnologies, Inc.
A clinical-stage company developing gene therapies for ocul…
|
ADVM | US | Manufacturing |
|
Advicenne
A specialty pharmaceutical company developing treatments fo…
|
ALDVI | FR | Manufacturing |
|
AegirBio AB
A diagnostics company specializing in therapeutic drug moni…
|
AEGIR | SE | Manufacturing |
|
Aelis Farma
Biopharmaceutical company developing CB1 receptor inhibitor…
|
AELIS | FR | Manufacturing |
|
AEON Biopharma, Inc.
Clinical-stage company developing therapeutic applications …
|
AEON | US | Manufacturing |
|
Aequus Pharmaceuticals Inc.
Developing and commercializing specialty pharmaceutical pro…
|
AQS | CA | Manufacturing |
Nuvalent, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/30903/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=30903 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=30903 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=30903 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 30903}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Nuvalent, Inc. (id: 30903)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.